Relay Therapeutics Inc.

Relay Therapeutics is a Cambridge‑based clinical‑stage precision‑medicine company developing targeted oncology small‑molecule drugs—including RLY‑2608 (PI3Kα inhibitor for breast/solid tumors) and RLY‑4008 (FGFR2 inhibitor)—in partnership with Genentech, Elevar, and Pfizer.

Headquarters: United States (USA)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Professional Services
Industry: Biotechnology Research

Employees: 188
HQ: Cambridge

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
RLAY	Relay Therapeutics Inc. Cap: 1.4B	EQUITY	NGM	USD	US75943R1023	Active	📈